Boston Globe

News & Analysis

boston globe and genzyme corp. - All News and Analysis

• Pay for Cambridge, Mass.-based drug developer's CEO was tops in biotech field.

  - 2004-10-27

  By Ross Kerber, The Boston Globe Knight Ridder/Tribune Business News Oct. 27--Genzyme Corp. chief executive Henri A. Termeer's salary of $1.2 million last year was the highest of any in the biotechnology industry, according to a survey released yesterday. ...

  Tags: Benefits, Biotechnology, Boston Globe, Cambridge, CEO, compensation, developer, Genzyme Corp., salary

• Boston launches program to buy imported drugs.

  - 2004-07-22

  By Christopher Rowland, The Boston Globe Knight Ridder/Tribune Business News Jul. 22--Mayor Thomas M. Menino sent a strong message to Congress and the pharmaceutical industry yesterday by launching a pilot program to permit city employees and retirees to purchase prescription drugs ...

  Tags: Boston, Boston Globe, Canada, FDA, Genzyme Corp., Government

• Biotechnology firm to expand Boston drug plant, create up to 50 jobs.

  - 2004-07-21

  By Jeffrey Krasner, The Boston Globe Knight Ridder/Tribune Business News Jul. 21--Genzyme Corp. today will announce a major expansion of its Allston Landing drug plant in a move expected to add up to 50 jobs at the largest biotech manufacturing facility in...

  Tags: Biotechnology, Boston Globe, Genzyme Corp., job

• Dollars to Flow for Access at Democratic National Convention in Boston.

  - 2004-05-30

  By Raphael Lewis, The Boston Globe Knight Ridder/Tribune Business News May 30--Corporations, special interests, and labor unions are planning lavish parties during the Democratic National Convention in Boston, spending hundreds of thousands of dollars each and gaining direct access to major...

  Tags: American International Group Inc., Biotechnology, Boston, Boston Globe, Democratic Party, Genzyme Corp., Massachusetts, senator, Strategy

• Mergers Hit Bottom Lines of Many Massachusetts Biotech Firms in 2003.

  - 2004-05-18

  By Christopher Rowland,, The Boston Globe Knight Ridder/Tribune Business News May 18--Investors are accustomed to biotechnology companies losing money. But the biggest money losers in Massachusetts over the last year -- on paper at least -- are surprises. They are the among...

  Tags: accounting, Biogen Idec Inc., Biotechnology, Boston Globe, FINANCE, Genzyme Corp., Investment, merger, writeoff

• The Boston Globe Business Briefs Column.

  - 2004-02-24

  The Boston Globe Knight Ridder/Tribune Business News Feb. 24--EXELON TO TURN OVER 3 PLANTS BY SUMMER: Exelon Corp. said it reached terms to turn over control of three Boston-area power plants to a consortium of banks by summer. It also resolved its lawsuits...

  Tags: Boston Globe, Exelon Corp., Genzyme Corp., Raytheon Co.

• The Boston Globe Biotechnology Briefs Column.

  - 2003-03-26

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Mar. 26--Shares in Biopure Corp. fell 58 cents, or 19 percent, yesterday to $2.45 after the Cambridge company sold 5.55 million shares at a price of $2.42 each. The company, which is fast...

  Tags: Biotechnology, Boston Globe, Cambridge, Genzyme Corp., Government

• Artificial Skin Doesn't Look Like Profit Boon Firms Once Hoped.

  - 2003-03-05

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Mar. 5--Not too long ago, investors poured hundreds of millions of dollars into firms pursuing the promise of artificial skin. Wooed by its potential to revolutionize the treatment of patients with severe burns...

  Tags: Boston Globe, Genzyme Corp., patient

• Career U-Turn Brings Ex-Counsel Back to Cambridge, Mass., Biotech Firm.

  - 2003-02-26

  By Jeffrey Krasner, The Boston Globe Knight Ridder/Tribune Business News Feb. 26----On Jan. 28, with considerable effort, Michael J. Astrue shaved and put on a tie. It was the first time he had attempted either task in 11 days. ...

  Tags: Biotechnology, board, Boston Globe, Cambridge, CAREER, director, FDA, Genzyme Corp., Government

• Shares Fall for Cambridge, Mass., Firm after Kidney Drug Fails to Perform.

  - 2002-11-28

  By Naomi Aoki, The Boston Globe Knight Ridder/Tribune Business News Nov. 28--Shares of Transkaryotic Therapies Inc. tumbled 33 percent yesterday after the Cambridge firm said a study failed to show its drug, Replagal, improves kidney function in patients with a rare inherited ...

  Tags: Boston Globe, FDA, Genzyme Corp., Government, patient